Basmisanil

Unknown / undisclosed

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Development in Schizophrenia stopped as a strategic decision by the sponsor. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Other / comorbidity
NCT07846215 · Newleos Therapeutics, Inc.
2026-12-01 – 2029-05-01 · Dup15Q Syndrome
What this study did
NCT05307679 · Hoffmann-La Roche
2022-12-16 – 2024-03-04 · Dup15q Syndrome
What this study did
NCT02928393 · Hoffmann-La Roche
2017-02-20 – 2017-11-03 · Stroke
What this study did
Phase 1 (1)
Other / comorbidity
NCT02534207 · Hoffmann-La Roche
2015-08 – 2015-11 · Healthy Volunteer
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Basmisanil to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
May 2029 (1)
Phase 2Dup15Q SyndromeNot yet recruiting
Est. primary completion 2029-05-01 · NCT07846215 · CT.gov ↗
What to watch

See the full readout calendar ↗